UHS closes $835M Talkspace acquisition, creating end-to-end behavioral health continuum
Andrew Cass / beckershospitalreview - King of Prussia, Pa.-based Universal Health Services has completed its acquisition of online behavioral health provider Talkspace in a deal valued at about $835 million. UHS and Talkspace first announced the deal in March and have now received all necessa…
AI Summary: UnitedHealth Services closed its $835 million acquisition of Talkspace, folding the virtual therapy platform into a broader behavioral-health strategy to expand access and create an end-to-end care continuum. The move accelerates digital mental-health integration at scale, promising greater capacity but also sparking debate about consolidation's effects on competition, quality, and clinician autonomy.
R1 drills down on AI prior authorizations with Humata buy
Jill Hughes / healthcaredive - The revenue cycle company wants to automate claims processing, and RI is banking that Humata’s track record of streamlining medical preapprovals should help further that goal.
AI Summary: R1 has moved to buy Humata Health, folding AI-driven prior authorization tools into its revenue-cycle stack. The acquisition targets faster, more automated approval workflows for payers and providers, promising efficiency gains — and the usual question: will automation fix paperwork or just rebrand it as “innovation”?
Cityblock inks deal to acquire Homeward Health to move into rural healthcare, lands $116M funding round
fiercehealthcare - Combined, the two companies will serve nearly 250,000 people and are positioned to reach the120 million people receiving government-funded healthcare in the U.S., Toyin Ajayi, Cityblock Health CEO and co-founder wrote in a blog post.
AI Summary: Cityblock Health has acquired Homeward Health, signaling a strategic push into rural Medicare services backed by fresh funding. The deal aims to blend Cityblock’s value-based, whole-person care model with Homeward’s rural footprint, promising expanded access — and yes, more venture-capital-fueled disruption in places that actually need care.
Providence to completely exit insurance business after Medicare Advantage deal falls through
Jakob Emerson / beckershospitalreview - Providence Health Plan will completely shut down after it was unable to reach a deal with a national insurer to operate its Medicare Advantage business. “We are in discussion with regulators about this development and the broader wind-down of Providence’s…
AI Summary: Providence announced it will completely exit the insurance business after a proposed Medicare Advantage transaction fell apart, triggering a wind‑down of its health plan. The move comes amid a broader operational turnaround that has shown sizable improvements but forces the system to refocus on core provider operations and financial stabilization.
- Providence $400M turnaround and CFO appointment (4)
- Providence Health Plan exits after Medicare Advantage deal (4)
- All Other Stories
Providence $400M turnaround and CFO appointment
Providence Health Plan exits after Medicare Advantage deal
All Other Stories
Hinge Health expands into gastrointestinal care with $105M acquisition
Rebecca Pifer Parduhn / healthcaredive - Hinge is purchasing Cylinder Health in a “logical extension” of the San Francisco-based company’s business, one analyst commented.
AI Summary: Hinge Health has moved into gastrointestinal care through a $105 million acquisition, signaling expansion beyond musculoskeletal digital health. Market observers and insiders offer contrasting views: some praise the strategic diversification and patient‑access potential, others question integration risks and whether digital models translate cleanly into GI service lines.
AstraZeneca Holds Preliminary Talks with Bristol Myers Squibb on Potential $400 Billion Merger
oncodaily - A deal that could create the world’s fourth-largest drugmaker British pharmaceutical leader AstraZeneca has held confidential, preliminary discussions regarding a potential combination with US rival Bristol Myers Squibb(BMS). A completed […]
AI Summary: AstraZeneca entered preliminary, non-binding talks with Bristol Myers Squibb about a potential $400 billion merger, probing whether combining pipelines and scale could reshape oncology and other businesses. The discussions are early, sparking market speculation and likely regulatory scrutiny as executives weigh strategic synergies against integration complexity and antitrust risk.
HCA Healthcare acquires 40 Texas urgent care centers
fiercehealthcare - The deal sees the facilities rebranded as CareNow sites, and many are being tied to the existing footprint of two affiliate systems.
AI Summary: Healthcare giant HCA has purchased 40 urgent care centers across Texas, folding dozens of local clinics into its national network. The move rapidly expands outpatient capacity and promises standardized operations and scale efficiencies — while predictably sparking questions about consolidation’s effects on pricing, local autonomy and patient experience.
Intermountain Health acquiring interests in 2 Idaho hospitals for $795M
fiercehealthcare - The nonprofit would become the sole owner of the 88-bed Idaho Falls Community Hospital and share ownership of the 38-bed Mountain View Hospital, It's been a minority investor in both since 2023.
AI Summary: Intermountain Health is acquiring Surgery Partners’ stake in two Idaho hospitals in a deal valued at roughly $795 million, expanding its regional footprint and consolidating local hospital operations. The transaction aims to stabilize services and investments in community care, though it will face the usual regulatory and integration headaches everyone pretends are quick.
Cardinal Health to buy Strive Medical, AdaptHealth's diabetes health business for $360M
fiercehealthcare - The pharmaceuticals and specialty products distributor plans to buy AdaptHealth's diabetes health business unit and medical supply provider Strive Medical in separate deals worth $360 million.
AI Summary: Cardinal Health agreed to buy AdaptHealth/Strive Medical’s diabetes health business for roughly $360 million and pursue additional acquisitions to expand its at‑home care portfolio. The moves aim to accelerate home‑based services and chronic disease support, reflecting a broader industry push to shift care out of hospitals and into patients' living rooms.
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
Intermountain Health, AdventHealth plan joint venture in Denver
Sydney Halleman / healthcaredive - AdventHealth is expected to have a majority interest in the partnership, which will unite Denver-area hospitals and clinics owned by the two nonprofits. The deal is expected to close early next year.
AI Summary: AdventHealth and Intermountain Health revealed plans to form a Denver-area joint venture to run a regional health plan, combining networks and payer capabilities to expand market reach. The deal aims to streamline care access and manage costs locally — a predictable playbook in health-system consolidation that shoppers and regulators will watch closely.
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
fiercehealthcare - Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.
AI Summary: Tempus is acquiring cancer-genomics company Personalis for roughly $1.5 billion to expand its testing and genomic-service footprint, betting bigger on integrated sequencing and AI-driven oncology diagnostics. The move accelerates Tempus’s push to scale tumor profiling and clinical assays nationwide — and yes, expect louder claims about “transforming cancer care.”
A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Frank Vinluan / medcitynews - Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A…
AI Summary: Novartis has struck a roughly $1 billion deal to acquire Myricx Bio, a preclinical bet aimed at securing a novel antibody‑drug conjugate payload. The move is a clear attempt to stand out in a crowded oncology market by buying potential innovation rather than inventing it in‑house — or, as finance folks call it, buying optionality.
IKS Health completes $557M TruBridge acquisition
Andrew Cass / beckershospitalreview - IKS Health has completed its $557 million acquisition of TruBridge, which provides revenue cycle management and EHR services for rural and community hospitals. Following the closing, TruBridge operates as a wholly owned subsidiary of IKS Health, according…
AI Summary: IKS Health has closed a $557 million deal to acquire TruBridge, integrating the acquired firm’s revenue-cycle and IT capabilities into IKS’s technology stack. The purchase accelerates IKS’s push to expand managed services for health systems, promising greater scale and product consolidation—because nothing says progress like buying your way into the future.
Ascension to Buy Tennessee Health System for Nearly $1B
Katie Adams / medcitynews - Ascension is set to acquire Williamson Health, a county-owned health system in Tennessee, in a deal worth nearly $1 billion. Ascension’s offer beat out bids from HCA Healthcare and Optum. The post Ascension to Buy Tennessee Health System for Nearly $1B ap…
AI Summary: Ascension announced plans to buy Williamson Health, an independent Tennessee health system, in a transaction valued at roughly $700M–$1B. The acquisition further consolidates hospital ownership in the region and will shift local governance and operational control to Ascension as the parties work through regulatory and integration steps.
American Hospital Association names Steve Walsh as next CEO
fiercehealthcare - Walsh is currently the head of the Massachusetts Hospital Association, and will be taking the national stage at a moment of substantial policy and political challenges for the hospital industry.
AI Summary: Steve Walsh was named the next CEO of the American Hospital Association, replacing outgoing leadership and signaling continuity with a public-sector advocacy background. The appointment centers on navigating hospital policy, membership priorities and advocacy at a time of industry consolidation and regulatory pressure — yes, more meetings and memos ahead.
As PBM industry shifts, LucyRx and Abarca Health merge to build scale
fiercehealthcare - Amid significant shifts in the pharmacy benefit management industry, LucyRx and Abarca Health have revealed plans to merge to build the scale necessary to compete in this changing landscape.
AI Summary: Two independent pharmacy benefit managers, LucyRx and Abarca Health, announced a combination to build scale amid industry consolidation. The deal aims to bolster negotiating leverage, broaden client reach and offer an alternative to dominant PBMs—because apparently one disruptor wasn’t enough to disrupt the disruptors.
Lifepoint closes acquisition of 8 ScionHealth hospitals
Kelly Gooch / beckershospitalreview - Brentwood, Tenn.-based Lifepoint Health has completed its acquisition of eight community hospitals from Louisville, Ky.-based ScionHealth. The hospitals are spread across six states, according to a June 2 news release. Lifepoint acquired: Lifepoint origin…
AI Summary: Lifepoint Health has finalized its purchase of eight community hospitals previously held by ScionHealth, consolidating regional services under a larger system. The deal promises operational integration and potential investment but also raises typical concerns about community access, continuity of care and how local staff will fare under new management.
Ascension must sell 7 ASCs to complete $3.9B AmSurg deal: FTC
Alan Condon / beckershospitalreview - St. Louis-based Ascension has received Federal Trade Commission approval to move forward with its planned acquisition of AmSurg — an ambulatory surgery center operator with more than 250 facilities across 34 states — but only after agreeing to divest seve…
AI Summary: The Federal Trade Commission approved Ascension’s $3.9 billion acquisition of AmSurg only after ordering divestitures of specific ambulatory surgery centers to preserve competition. Ascension must sell those ASCs before closing to prevent local market concentration and potential price hikes — because apparently somebody still has to protect patients from monopolies.
Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing
Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…
AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.